Atara BiotherapeuticsATRA
13F holders, Q2 2025 (June 30)At the end of Q2 2025, 32 institutions reported holding Atara Biotherapeutics Inc. (ATRA) in their 13F filings, down 5 from Q1 2025. 4 opened new positions and 9 sold out. The largest holders were EcoR1 Capital, LLC ($4.4M), Redmile Group, LLC ($3.4M) and Vanguard Group Inc. ($1.5M). 2 famous investors held it, including Ken Griffin (0.0% of Citadel Advisors's portfolio) and Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Atara Biotherapeutics Inc.
- CUSIP
- 046513206
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $709K |
| Exits | 9 | $830K |
All 13F filers, Q1 2025 → Q2 2025: 107,304 shares bought and 390,748 shares sold, net −283,444 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 32 holders
| EcoR1 Capital, LLC | 0.26% | No change | 573,183 | $4.4M |
| Redmile Group, LLC | 0.36% | No change | 441,701 | $3.4M |
| Vanguard Group Inc. | 0.00% | No change | 190,761 | $1.5M |
| Vestal Point Capital, LP | 0.04% | No change | 94,085 | $726K |
| Staley Capital Advisers Inc. | 0.02% | Reduce -6.3% | 75,000 | $579K |
| BlackRock, Inc. | 0.00% | Add +16.5% | 70,848 | $547K |
| Acadian Asset Management LLC | 0.00% | Reduce -43.4% | 65,155 | $502K |
| Geode Capital Management, LLC | 0.00% | Add +2.5% | 60,136 | $464K |
| Marshall Wace, LLP | 0.00% | New | 42,355 | $327K |
| State Street Corp. | 0.00% | No change | 25,253 | $195K |
| Citadel Advisors | 0.00% | New | 23,003 | $178K |
| Mackenzie Financial Corp. | 0.00% | New | 22,514 | $174K |
| Gsa Capital Partners LLP | 0.01% | Add +1.1% | 19,591 | $151K |
| FMR LLC | 0.00% | Reduce -0.0% | 17,156 | $132K |
| Renaissance Technologies | 0.00% | Reduce -2.9% | 16,936 | $131K |
| Morgan Stanley | 0.00% | Add +26.2% | 14,926 | $115K |
| Bridgeway Capital Management, LLC | 0.00% | No change | 14,000 | $108K |
| Northern Trust Corp. | 0.00% | No change | 11,170 | $86K |
| UBS Group AG | 0.00% | Reduce -65.5% | 8,385 | $65K |
| Bank of America Corp. | 0.00% | Reduce -95.9% | 7,688 | $59K |
| Raymond James Financial Inc. | 0.00% | New | 4,021 | $31K |
| Royal Bank of Canada | 0.00% | Add +70.6% | 1,450 | $12K |
| SBI Securities Co., Ltd. | 0.00% | No change | 1,404 | $11K |
| Wells Fargo & Company | 0.00% | No change | 951 | $7K |
| Jones Financial Companies LLLP | 0.00% | No change | 703 | $6K |
| JPMorgan Chase & Co. | 0.00% | No change | 216 | $2K |
| Raiffeisen Bank International AG | 0.00% | No change | 200 | $2K |
| Banque Transatlantique SA | 0.00% | No change | 176 | $1K |
| Rhumbline Advisers | 0.00% | No change | 175 | $1K |
| Group One Trading LLC | 0.00% | No change | 148 | $1K |
| BNP Paribas Financial Markets | 0.00% | No change | 50 | $386 |
| Osaic Holdings, Inc. | 0.00% | No change | 10 | $77 |
"% of holder's portfolio" is ATRA's weight in each manager's 13F, not the share of Atara Biotherapeutics Inc. the manager owns.